TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25230962
Drug: Intracameral triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral triamcinolone acetonide (2 mg/0.05 ml)
Study: 18006530
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at target Ce of 4 ng ml(‐1)
Study: 18006530
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at target Ce of 6 ng ml(‐1)
Study: 18006530
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at target Ce of 2 ng ml(‐1)
Study: 7774173
Drug: 0.5% HF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% HF solution applied three times
Study: 7774173
Drug: 0.5% HF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% HF solution (12-13 yr-olds)
Study: 2182310
Drug: RU486 alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU486 alone (600mg in a single oral dose)
Study: 2182310
Drug: RU486 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU486 and PG (1 mg suppository)
Study: 7356891
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg L.A. propranolol
Study: 7356891
Drug: L.A. propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: L.A. propranolol
Study: 30770892
Drug: Delta-9-tetrahydrocannabinol (Δ9-THC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta-9-tetrahydrocannabinol (Δ9-THC; 1.19 mg/2 ml)
Study: 30739626
Drug: 250 mg/d
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/d Mg as magnesium oxide (n=27)
Study: 23721562
Drug: Maudsley Model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maudsley Model of Treatment for Adults with Anorexia Nervosa (MANTRA)
Study: 17106140
Drug: CR‐ISMN (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR‐ISMN (40 mg once daily)
Study: 12751378
Drug: High-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) therapy
Study: 9322520
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of lamivudine
Study: 3087293
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with MMC and 5‐FU (group A)
Study: 23018285
Drug: Avagacestat 200
Normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avagacestat 200 mg
Study: 23018285
Drug: Avagacestat 400
Normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avagacestat 400 mg
Study: 23018285
Drug: Avagacestat 50
Normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avagacestat 50 mg
Study: 9322631
Drug: Prepidil (intracervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepidil (intracervical prostaglandin E2 gel)
Study: 9322631
Drug: Cervidil (controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervidil (controlled-release hydrogel pessary)
Study: 8173721
Drug: Ceftizoxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime (1 gram single dose)
Study: 8173721
Drug: Cefoxitin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (3 doses of 2 grams)
Study: 2895596
Drug: Single small
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single small oral dose of a beta-adrenergic blocking agent (labetalol, atenolol, or oxprenolol)
Study: 19395280
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump infusion line not changed for up to 100 hours
Study: 1396252
Drug: Surfactant-TA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant-TA (100 mg/kg) administered within 30 min of birth (early group)
Study: 1396252
Drug: Surfactant-TA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant-TA (100 mg/kg) administered at 6 h of age (late group)
Study: 1396252
Drug: Surfactant-TA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant-TA (100 mg/kg) administered early
Study: 4039775
Drug: Metoclopramide (MCL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (MCL, Paspertin, loading infusion 0.5 mg/kg body wt./h over 2 h, maintenance infusion 0.25 mg/kg/h over 24 h)
Study: 4039775
Drug: Haloperidol (HAL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (HAL, Haldol, 1/10 of MCL dosage)
Study: 4039775
Drug: Triflupromazine (TFP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflupromazine (TFP, Psyquil, 1/2 of MCL dosage)
Study: 27219465
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (3 mg drospirenone plus 30 μg ethinyloestradiol)
Study: 27219465
Drug: Polyvitamin tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvitamin tablets
Study: 22385102
Drug: Combination peel
Normalized name: orange peel extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination peel with fractional prickle coral calcium (FCR™)
Study: 20138102
Drug: 5-HTP administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HTP administration
Study: 11394491
Drug: TENS applied
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS applied to the Hegyu acupuncture point (L.I.4) for 15 minutes
Study: 8209275
Drug: Cisplatin-containing chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin-containing chemotherapy plus radiotherapy
Study: 3059277
Drug: Vancomycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (10 mg/kg I.V. q 6 H, day -5 to +1)
Study: 28257160
Drug: Protein 0
Normalized name: OspA protein 0.06 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein 0 g (control)
Study: 28257160
Drug: Protein 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein 12.5 g
Study: 28257160
Drug: Protein 25
Normalized name: Protein 250 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein 25 g
Study: 28257160
Drug: Protein 50
Normalized name: Glycoprotein 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein 50 g
Study: 28257160
Drug: Protein 75
Normalized name: antihemophilic factor (FVIII) recombinant, Fc fusion protein 750 unit INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein 75 g
Study: 26403339
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy at various doses (grouped as >0% to 12.5%, >12.5% to 25%, >25% to 50%, and >50% of target dose)
Study: 26403339
Drug: >0% to
Approvals — FDA: no, EMA: no, PMDA: no
Description: >0% to 12.5% of target dose
Study: 26403339
Drug: >12.5% to
Approvals — FDA: no, EMA: no, PMDA: no
Description: >12.5% to 25% of target dose
Study: 26403339
Drug: >25% to
Approvals — FDA: no, EMA: no, PMDA: no
Description: >25% to 50% of target dose
Study: 19085498
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL ropivacaine (0.2%) intraarticularly plus 30 mL saline in the extraarticular wound space
Study: 19085498
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL ropivacaine (0.2%) intraarticularly plus 30 mL ropivacaine (0.2%) in the extraarticular wound space
Study: 17205877
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1% tropicamide and 10% phenylephrine (Group A)
Study: 17205877
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of 1% tropicamide and 10% phenylephrine (Group B)
Study: 7577294
Drug: Extradural anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural anaesthesia with Bupivacaine 0.5% (20 ml) at L2-3
Study: 7261940
Drug: Propranolol with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol with increased diuretic component
Study: 7261940
Drug: Laboratory tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laboratory tests during treatment
Study: 22155904
Drug: Valacyclovir (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (2 g four times daily)
Study: 25424991
Drug: Valganciclovir (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir (900 mg daily)
Study: 20959530
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/day) with exercise training (1.5-2 h/day, 3 days/wk)
Study: 20959530
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/day) alone
Study: 19212305
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment for hepatitis C
Study: 19212305
Drug: Specifically Targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specifically Targeted Antiviral Therapy for HCV (STAT-C)
Study: 15213207
Drug: Pooled hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pooled hormone therapy (CEE combined with CEE plus MPA)
Study: 9549834
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (5 mg sublingual tablet)
Study: 7528449
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) after successful cytoreductive chemotherapy
Study: 7528449
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during induction, consolidation, and the first two cycles of maintenance chemotherapy
Study: 3382060
Drug: Oral metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metaproterenol sulfate (MS) 0.4 mg/kg
Study: 3382060
Drug: Oral metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metaproterenol sulfate (MS) 0.6 mg/kg
Study: 3382060
Drug: Oral metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metaproterenol sulfate (MS) 0.8 mg/kg
Study: 31416827
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (0.15 mg/kg)
Study: 31416827
Drug: Prednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1 mg/kg)
Study: 25646337
Drug: Iron‐folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron‐folic acid (IFA) capsule
Study: 25646337
Drug: Multiple micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrients (MMN) capsule
Study: 25646337
Drug: 20-g sachet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-g sachet of small‐quantity lipid‐based nutrient supplement (SQ‐LNS)
Study: 24029861
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol 20 µg daily
Study: 20818838
Drug: Gabapentin ER
Normalized name: gabapentin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin ER QD (total daily dose 1800 mg)
Study: 20818838
Drug: Gabapentin ER
Normalized name: gabapentin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin ER DD (total daily dose 1800 mg)
Study: 17995820
Drug: Chocolate mix
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chocolate mix with 2.45 g of milk proteins
Study: 15975326
Drug: Vitamin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin treatment to lower homocysteine
Study: 15975326
Drug: Antithrombotic, anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic, anticoagulant and surgical treatments
Study: 16336447
Drug: 0.06 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/kg midazolam
Study: 467206
Drug: Divided dose
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided dose of X-Prep Liquid
Study: 19453810
Drug: Two-compound scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound scalp formulation (calcipotriol 50 microg/g plus betamethasone 0.5 mg/g as dipropionate; Xamiol)
Study: 19453810
Drug: Calcipotriol scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol scalp solution (50 microg/mL; Daivonex)
Study: 14872413
Drug: 90 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 microg/kg rFVIIa every 2 to 3 hours for two or three doses
Study: 3631470
Drug: Nalbuphine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 3 mg
Study: 3631470
Drug: Pethidine 15
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 15 mg
Study: 31952047
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate (NaHCO3) supplementation (0.3 g/kg body mass)
Study: 31952047
Drug: Placebo supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplements (amylum solani, magnesium stearate, and sunflower oil capsules)
Study: 22685233
Drug: Subcutaneous glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous glargine (0.25 U/kg body weight)
Study: 18657398
Drug: Work therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work therapy
Study: 11344179
Drug: HRT-only (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT-only (conjugated equine estrogens 0.625 mg)
Study: 11344179
Drug: Combined risedronate-HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined risedronate-HRT (risedronate 5 mg + conjugated equine estrogens 0.625 mg)
Study: 7859805
Drug: Neomycin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin (1.5 g per day)
Study: 7859805
Drug: Pravastatin and
Normalized name: pravastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin and neomycin in combination
Study: 7859805
Drug: Sitostanol ester
Normalized name: disodium ascorbyl sitostanol phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitostanol ester (1.5 g per day)
Study: 200256
Drug: graduated doses
Normalized name: MEDICINE DOSE CUP GRADUATED 30ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: graduated doses of mestranol up to 50 microgram
Study: 200256
Drug: conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conjugated equine oestrogen (1.25 mg daily)
Study: 200256
Drug: oestrogen valerate
Normalized name: valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: oestrogen valerate (2 mg daily)
Study: 23442899
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor monotherapy
Study: 19735957
Drug: Jelly containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jelly containing 5 g sc-FOS and 0.3 g Sideritis euboea extract
Study: 15727147
Drug: Fluconazole (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (0.2 g orally once a day)
Study: 15727147
Drug: Itraconazole (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (0.2 g orally twice a day)
Study: 15727147
Drug: Ketoconazole (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (0.2 g orally twice a day)
Study: 10083765
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg per day
Study: 3520796
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg three times a day
Study: 26964995
Drug: Elisidepsin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elisidepsin (10 mg flat dose, Arm A)
Study: 26964995
Drug: Elisidepsin (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elisidepsin (3.75 mg flat dose, Arm B)
Study: 18954461
Drug: AR7 Joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR7 Joint Complex (1 capsule daily for 12 weeks)
Study: 18954461
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 capsule daily for 12 weeks)
Study: 12523884
Drug: argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: argon laser trabeculoplasty plus topical betaxolol
Study: 10351929
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of dry powder mannitol (approximately 300 mg)
Study: 9015926
Drug: Acetaminophen method
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen method for gastric emptying of liquid food
Study: 9015926
Drug: Correlation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation with serum acetaminophen concentration (45 min value)
Study: 2860913
Drug: Atracurium (larger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (larger doses)
Study: 31922272
Drug: Superficial Shaving
Normalized name: Shave Grass Top
DrugBank: Equisetum arvense top (DB14349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial Shaving combined with Photodynamic Therapy (SS‐PDT)
Study: 29370788
Drug: Single-dose radial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose radial extracorporeal shock wave therapy (rESWT)
Study: 29370788
Drug: Local corticosteroid
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local corticosteroid injection (LCsI)
Study: 18570681
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) in individual format (10 sessions)
Study: 18570681
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) in group format (10 sessions)
Study: 18570681
Drug: Standardized recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized recommended treatment for somatization disorder in primary care (Smith's norms)
Study: 17384957
Drug: Patients' perception
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients' perception of being involved in treatment
Study: 15471826
Drug: SCC-Ag >
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCC-Ag > or = 4 ng/mL
Study: 11302268
Drug: Supportive‐expressive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive‐expressive therapy (SE)
Study: 3731566
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg administered three times daily
Study: 3731566
Drug: Propranolol 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 240 mg daily
Study: 29198193
Drug: Phosphatidylcholine (PC)
Normalized name: phosphatidylcholine, soybean
DrugBank: Lecithin (DB15834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylcholine (PC) treatment in primary hepatocytes
Study: 29198193
Drug: siRNA for
Normalized name: Sirna-027
DrugBank: Sirna-027 (DB05896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: siRNA for CTP: choline phosphate cytidylyltranferase α (CCTα) treatment in primary hepatocytes
Study: 25795256
Drug: MenABCWY formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenABCWY formulation (full dose OMV)
Study: 25795256
Drug: MenABCWY formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenABCWY formulation (one-quarter dose OMV)
Study: 25795256
Drug: MenABCWY formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenABCWY formulations
Study: 24021044
Drug: Piperacillin/tazobactam (TZP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (TZP) 4.5 g, prolonged infusion every 6 hours for 3 hours
Study: 24021044
Drug: Piperacillin/tazobactam (TZP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (TZP) 4.5 g, regular infusion every 6 hours for 30 minutes
Study: 19452245
Drug: Conventional disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional disease-modifying anti-rheumatic drugs (DMARDs)
Study: 3332805
Drug: Clonidine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (average dose 0.4 mg/day)
Study: 30039159
Drug: Oxygen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen (10 L per minute by nonrebreather facemask until delivery)
Study: 26115789
Drug: Previous stimulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous stimulant medication history
Study: 29200411
Drug: Bicyclol 25
Normalized name: alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
DrugBank: Biperiden (DB00810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicyclol 25 mg three times daily
Study: 24081374
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (α-tocopherol) 100 mg three times daily
Study: 11733660
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol-alfentanil
Study: 27515095
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection (2.5 mL of bupivacaine, 2.5 mg of morphine and 1 mL of betamethasone, 6 mL of fluid injection)
Study: 26686847
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg daily for 12 weeks)
Study: 22710607
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day p.o.) plus gemcitabine (1000 mg/m2, days 1, 8, 15, every 4 weeks)
Study: 20074372
Drug: Intermittent screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent screening and treatment (IST)
Study: 15652874
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg/day)
Study: 1340245
Drug: Oral hydration
Normalized name: terpin hydrate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydration with rehydration salts
Study: 6147285
Drug: loprazolam (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: loprazolam (1.0 mg)
Study: 6147285
Drug: nitrazepam (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrazepam (5.0 mg)